Ibandronate and calcitriol reduces fracture risk, reverses bone loss, and normalizes bone turnover after lTX

Transplantation

Volumn 93, Issue 3, 2012, Pages 331-336

  Wagner, Doris ^a   Amrein, Karin ^a   Dimai, Hans Peter ^a   Kniepeiss, Daniela ^a   Tscheliessnigg, Karl Heinz ^a   Kornprat, Peter ^a   Dobnig, Harald ^a   Pieber, Thomas ^a   Fahrleitner Pammer, Astrid ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Calcitriol; Ibandronate; Immunosuppression; Liver transplantation; Osteoporosis; Renal insufficiency; Secondary hyperpara thyroidism

Indexed keywords

ALKALINE PHOSPHATASE; ANALGESIC AGENT; CALCITRIOL; CALCIUM; CYCLOSPORIN A; IBANDRONIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OSTEOCALCIN; PREDNISOLONE; TACROLIMUS; VITAMIN D;

ADULT; AGE; ALCOHOL LIVER CIRRHOSIS; ARTICLE; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE MINERAL; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRACTURE; GENDER; HUMAN; INCIDENCE; LIVER TRANSPLANTATION; LOW DRUG DOSE; MALE; NUTRITIONAL STATUS; OSTEOLYSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION;

ALKALINE PHOSPHATASE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CALCITRIOL; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; FEMALE; FRACTURES, BONE; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; OSTEOPOROSIS; PARATHYROID HORMONE; RISK;

EID: 84856491071     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31823f7f68     Document Type: Article

References (26)

1. Mells G, Neuberger J. Long-term care of the liver allograft recipient. Semin Liver Dis 2009; 29: 102.
2. Carey EJ, Balan V, Kremers WK, et al. Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: Not just a cholestatic problem. Liver Transpl 2003; 9: 1166.
3. Stein EM, Cohen A, Freeby M, et al. Severe vitaminDdeficiency among heart and liver transplant recipients. Clin Transplant 2009; 23: 861.
4. Porayko MK, Wiesner RH, Hay JE, et al. Bone disease in liver transplant recipients: Incidence, timing, and risk factors. Transplant Proc 1991; 23(1 Pt 2): 1462.
5. Bonkovsky HL, Hawkins M, Steinberg K, et al. Prevalence and prediction of osteopenia in chronic liver disease. Hepatology 1990; 12: 273.
6. Rouillard S, Lane NE. Hepatic osteodystrophy. Hepatology 2001; 33: 301.
7. Fahrleitner A, Prenner G, Kniepeiss D, et al. Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status. Wien Klin Wochenschr 2002; 114: 717.
8. Stellon AJ, Webb A, Compston J, et al. Low bone turnover state in primary biliary cirrhosis. Hepatology 1987; 7: 137.
9. Compston JE. Osteoporosis after liver transplantation. Liver Transpl 2003; 9: 321.
10. Fahrleitner-Pammer A, Piswanger-Soelkner JC, Pieber TR, et al. Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: A randomized double-blind, placebocontrolled trial. J Bone Miner Res 2009; 24: 1335.
11. Bodingbauer M, Pakrah B, Kristo I, et al. Non-persistent effect of shortterm bisphosphonate treatment in preventing fractures after liver transplantation. Transpl Int 2009; 23: 118.
12. Ninkovic M, Skingle SJ, Bearcroft PW, et al. Incidence of vertebral fractures in the first three months after orthotopic liver transplantation. Eur J Gastroenterol Hepatol 2000; 12: 931.
13. Cohen A, Shane E. Osteoporosis after solid organ and bone marrow transplantation. Osteoporos Int 2003; 14: 617.
14. Kwan JT, Almond MK, Evans K, et al. Changes in total body bone mineral content and regional bone mineral density in renal patients following renal transplantation. Miner Electrolyte Metab 1992; 18: 166.
15. Reeves HL, Francis RM, Manas DM, et al. Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation. Liver Transplantation Surg 1998; 4: 404.
16. GuichelaarMM,Schmoll J, Malinchoc M, et al. Fractures and avascular necrosis before and after orthotopic liver transplantation: Long-term follow-up and predictive factors. Hepatology 2007; 46: 1198.
17. Premaor MO, Das TK, Debiram I, et al. Fracture incidence after liver transplantation: Results of a 10-year audit. QJM 2011; 104: 599.
18. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994; 4: 368.
19. Wagner D, Fahrleitner-Pammer A. Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: Are they of any help? Wien Med Wochenschr2010 160 452.
20. Genant HK, Wu CY, van Kuijk C, et al. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993; 8: 1137.
21. Feller RB, McDonald JA, Sherbon KJ, et al. Evidence of continuing bone recovery at a mean of 7 years after liver transplantation. Liver Transpl Surg 1999; 5: 407.
22. Siris ES, Selby PL, Saag KG, et al. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009; 122(2 suppl): S3.
23. Downey TW, Foltz SH, Boccuzzi SJ, et al. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. S Med J 2006; 99: 570.
24. Bodingbauer M, Wekerle T, Pakrah B, et al. Prophylactic bisphosphonate treatment prevents bone fractures after liver transplantation. Am J Transpl 2007; 7: 1763.
25. Crawford BA, Kam C, Pavlovic J, et al. Zoledronic acid prevents bone loss after liver transplantation: A randomized blind, placebo controlled trial. Ann Intern Med 2006; 144: 239.
26. Kasturi KS, Chennareddygari S, Mummadi RR. Effect of bisphosphonates on bone mineral density in liver transplant patients: A meta-analysis and systematic review of randomized controlled trials. Transpl Int 2009; 23: 200.